SG11201503765XA - METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF - Google Patents

METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF

Info

Publication number
SG11201503765XA
SG11201503765XA SG11201503765XA SG11201503765XA SG11201503765XA SG 11201503765X A SG11201503765X A SG 11201503765XA SG 11201503765X A SG11201503765X A SG 11201503765XA SG 11201503765X A SG11201503765X A SG 11201503765XA SG 11201503765X A SG11201503765X A SG 11201503765XA
Authority
SG
Singapore
Prior art keywords
forms
oxidopyridyn
cristal
cyclopropylmethoxy
methoxypyridine
Prior art date
Application number
SG11201503765XA
Other languages
English (en)
Inventor
Pascal Billot
Didier Brige
Alexandre Giuliani
Hagit Elmaleh
Marc-Antoine Perrin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201503765XA publication Critical patent/SG11201503765XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201503765XA 2012-11-28 2013-11-28 METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF SG11201503765XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306479 2012-11-28
PCT/EP2013/074972 WO2014083107A1 (en) 2012-11-28 2013-11-28 METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF

Publications (1)

Publication Number Publication Date
SG11201503765XA true SG11201503765XA (en) 2015-06-29

Family

ID=47324005

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503765XA SG11201503765XA (en) 2012-11-28 2013-11-28 METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF

Country Status (13)

Country Link
US (1) US9533953B2 (zh)
EP (1) EP2935219A1 (zh)
JP (1) JP2016500094A (zh)
KR (1) KR20150087252A (zh)
CN (1) CN104955808A (zh)
AU (1) AU2013351146A1 (zh)
BR (1) BR112015011849A2 (zh)
CA (1) CA2892156A1 (zh)
IL (1) IL238828A0 (zh)
MX (1) MX2015006807A (zh)
RU (1) RU2621894C2 (zh)
SG (1) SG11201503765XA (zh)
WO (1) WO2014083107A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0711282T3 (da) * 1993-07-28 2002-09-16 Aventis Pharma Ltd Forbindelser som PDE IV og TNF inhibitorer
EP1519922A1 (en) * 2002-07-02 2005-04-06 Merck Frosst Canada & Co. Di-aryl-substituted ethane pyridone pde4 inhibitors
FR2915100B1 (fr) * 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
FR2915099B1 (fr) * 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
FR2915098B1 (fr) * 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Also Published As

Publication number Publication date
JP2016500094A (ja) 2016-01-07
US20150322014A1 (en) 2015-11-12
CA2892156A1 (en) 2014-06-05
IL238828A0 (en) 2015-06-30
AU2013351146A1 (en) 2015-06-11
RU2015125304A (ru) 2017-01-11
RU2621894C2 (ru) 2017-06-08
EP2935219A1 (en) 2015-10-28
CN104955808A (zh) 2015-09-30
WO2014083107A1 (en) 2014-06-05
KR20150087252A (ko) 2015-07-29
US9533953B2 (en) 2017-01-03
BR112015011849A2 (pt) 2017-07-11
MX2015006807A (es) 2016-01-14

Similar Documents

Publication Publication Date Title
HK1209736A1 (zh) -取代的苯甲酰胺及其使用方法
HK1223913A1 (zh) 經取代的苯甲酰胺及其使用方法
HK1205938A1 (zh) 抑制劑及其應用方法
EP2831195A4 (en) MICROEMULSION REFLUX ADJUVANT COMPOSITION AND METHOD OF USE
EP2803657A4 (en) CRYSTAL FORM OF PROSTAGLANDINANALOGA AND METHOD OF PREPARING THEREOF AND USE THEREOF
EP2808318A4 (en) CRYSTALLINE FORM OF PROSTAGLANDIN ANALOGUE, PROCESS FOR PREPARING SAME AND USE THEREOF
EP2573070A4 (en) CRYSTAL FORM OF (S) -4-HYDROXY-2-OXO-1-PYRROLIDINACETAMIDE, METHOD OF MANUFACTURE AND USE THEREOF
ZA201406145B (en) Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
HRP20181704T1 (hr) Kristalni oblik kidamida, metoda pripreme i uporabe istog
EP2744422A4 (en) SUTURE PASSING INSTRUMENTS AND METHOD OF USE
EP2672820A4 (en) MANNOSID COMPOUNDS AND METHOD OF USE THEREOF
EP2938341A4 (en) Heterocyclic compounds and methods for the use thereof
EP2834421A4 (en) STABILIZING AGENTS AND METHODS OF USE
PL2814463T3 (pl) Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania
HK1193087A1 (zh) 阿戈美拉汀的新晶型 、其製備方法、應用和包含其的藥物組合物
EP2844219A4 (en) SENSITIZING COMPOSITION AND METHOD OF USE
IL234492A (en) Crystalline forms of 5α - androstane - 3 β, 56β, - triol and methods for their preparation
GB201223374D0 (en) Personal care composition and methods of making the same
HK1210143A1 (zh) 氮雜環丁烷酮化合物的晶型及其製備方法
IL238828A0 (en) Process for preparing crystalline forms of 4-(cyclopropylmethoxy-3,5)-n-(dichloro-1-oxidopyridine-4-yl)-5-methoxypyridine-2-carboxamide and crystalline forms formed in the process
AU2013901754A0 (en) Fabric care composition and method of use thereof
IL238829B (en) Process for the preparation of 4-(cyclopropylmethoxy-3,5)-n-(dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide